Durable immune responses after BNT162b2 vaccination in home-dwelling old adults
Open Access
- 10 January 2023
- journal article
- research article
- Published by Elsevier in Vaccine: X
- Vol. 13, 100262
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Correlates of protection against SARS-CoV-2 in rhesus macaquesNature, 2020
- SARS-CoV-2–Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort StudyThe Journal of Infectious Diseases, 2020
- Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort studyBMJ, 2020
- SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognitionNature Immunology, 2020
- The Exclusion of Older Persons From Vaccine and Treatment Trials for Coronavirus Disease 2019—Missing the TargetJAMA Internal Medicine, 2020
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controlsNature, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigenProceedings of the National Academy of Sciences, 2017
- Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cellsBlood, 2009